Anti-tumor activity of the combination of bendamustine with vorinostat in diffuse large B-cell lymphoma cells.

Fernández Rodríguez, M. Concepción; Salar Silvestre, Antonio; Navarro, Alfons; Gimeno Vázquez, Eva; Pairet García, Silvia; Camacho Díaz, Laura; Ferraro Rosset, Mariana Paola; Serrano Figueras, Sergi; Besses Raebel, Carles; Bellosillo Paricio, Beatriz; Sanchez Gonzalez, Blanca

Anti-tumor activity of the combination of bendamustine with vorinostat in diffuse large B-cell lymphoma cells.

Mostra el registre complet Registre parcial de l'ítem

dc.contributor.author Fernández Rodríguez, M. Concepciónca
dc.contributor.author Salar Silvestre, Antonioca
dc.contributor.author Navarro, Alfonsca
dc.contributor.author Gimeno Vázquez, Evaca
dc.contributor.author Pairet García, Silviaca
dc.contributor.author Camacho Díaz, Lauraca
dc.contributor.author Ferraro Rosset, Mariana Paolaca
dc.contributor.author Serrano Figueras, Sergica
dc.contributor.author Besses Raebel, Carlesca
dc.contributor.author Bellosillo Paricio, Beatrizca
dc.contributor.author Sanchez Gonzalez, Blancaca
dc.date.accessioned 2016-03-30T07:11:58Z
dc.date.issued 2016
dc.description.abstract Current standard-of-care therapy for diffuse large B-cell lymphoma (DLBCL) results in up to 40% of patients who either relapse or develop refractory disease. In this setting, further therapeutic improvements are needed. This study analyzed the in vitro effects of the combination of bendamustine with the histone deacetylase inhibitor vorinostat in DLBCL cells. This combination enhanced histone acetylation and double strand DNA breaks resulting in an additive to synergistic cytotoxic effect in both ABC- and GCB-type DLBCL cells, independently of their TP53 mutational status. These results support the rationale for considering bendamustine and vorinostat combination as a novel approach in DLBCL treatment.ca
dc.description.sponsorship This work was supported by grants from AECC Cataluña 2009, 2014 SGR 567, Instituto de Salud Carlos III FEDER (PT13/0010/0005) and the “Xarxa de Bancs de tumors” sponsored by Pla Director d’Oncologia de Catalunya (XBTC). Concepción Fernández-Rodríguez received a fellowship from the Ministry of Economy and Competitiveness of Spain (PFIS grant FI11/00353)
dc.format.mimetype application/pdfca
dc.identifier.citation Fernández-Rodríguez C, Salar A, Navarro A, Gimeno E, Pairet S, Camacho L. et al. Anti-tumor activity of the combination of bendamustine with vorinostat in diffuse large B-cell lymphoma cells. Leuk Lymphoma. 2016 Mar;57(3):692-9. doi: 10.3109/10428194.2015.1063143ca
dc.identifier.doi http://dx.doi.org/10.3109/10428194.2015.1063143
dc.identifier.issn 1026-8022
dc.identifier.uri http://hdl.handle.net/10230/26032
dc.language.iso engca
dc.publisher Taylor & Francisca
dc.relation.ispartof Leuk Lymphoma. 2016 Mar;57(3):692-9
dc.rights © Taylor & Francis. This is an electronic version of an article published in Fernández-Rodríguez C, Salar A, Navarro A, Gimeno E, Pairet S, Camacho L. et al. Anti-tumor activity of the combination of bendamustine with vorinostat in diffuse large B-cell lymphoma cells. Leuk Lymphoma. 2016 Mar;57(3):692-9. Leuk Lymphoma is available at http://dx.doi.org/10.3109/10428194.2015.1063143ca
dc.rights.accessRights info:eu-repo/semantics/openAccessca
dc.subject.other Tumors -- Tractamentca
dc.title Anti-tumor activity of the combination of bendamustine with vorinostat in diffuse large B-cell lymphoma cells.ca
dc.type info:eu-repo/semantics/articleca
dc.type.version info:eu-repo/semantics/acceptedVersionca

Col·leccions

Articles (Hospital del Mar Research Institute)
Articles (Departament de Medicina i Ciències de la Vida)